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Abstract
Objective—The dominant-negative mutation, P467L, in Peroxisome Proliferator Activated
Receptor gamma (PPARγ) affects adipose tissue distribution, insulin sensitivity and blood
pressure in heterozygous humans. We hypothesized that the equivalent mutation, PPARγ-P465L,
in mice will worsen atherosclerosis.
Methods and Results—ApolipoproteinE-null mice with and without PPARγ-P465L mutation
were bred in 129S6 inbred genetic background. Mild hypertension and lipodystrophy of PPARγ-
P465L persisted in the apoE-null background. Glucose homeostasis was normal, but plasma
adiponectin was significantly lower and resistin was higher in PPARγ-P465L mice. Plasma
cholesterol and lipoprotein distribution were not different, but plasma triglycerides tended to be
reduced. Surprisingly, there were no overall changes in the atherosclerotic plaque size or
composition. PPARγ-P465L macrophages had a small decrease in CD-36 mRNA and a small yet
significant reduction in VLDL uptake in culture. In unloaded apoE-null macrophages with
PPARγ-P465L, cholesterol uptake was reduced while apoAI-mediated efflux was increased.
However, when cells were cholesterol loaded in presence of acetylated LDL, no genotype
difference in uptake or efflux was apparent. A reduction of VCAM1 expression in aorta suggests a
relatively anti-atherogenic vascular environment in mice with PPARγ-P465L.
Conclusions—Small, competing pro- and anti-atherogenic effects of PPARγ-P465L mutation
result in unchanged plaque development in apoE-deficient mice.
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Introduction
Most individuals with cardiovascular disease (CVD) have multiple risk factors including
dyslipidemia, hypertension, abdominal obesity, insulin resistance, and pro-inflammatory and
pro-thrombotic state, which together constitute the Metabolic Syndrome (MetS).1 Although
insulin resistance is a significant component of MetS, diabetes by itself can make patients
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more susceptible to atherosclerotic disease and also increases the severity of pre-existing
cardiovascular disease. Many diabetic patients are being treated with Peroxisome
Proliferator Activated Receptor gamma (PPARγ) agonist Thiazolidinedione drugs, which
act as insulin sensitizers. Multiple studies have demonstrated the anti-atherosclerotic effects
of PPARγ agonists using mouse models of atherosclerosis lacking apolipoprotein E (apoE)
or low-density lipoprotein receptor (LDLR).2–4 PPARγ is a nuclear receptor, and amongst
its myriad functions, is necessary for adipocyte differentiation and triglyceride deposition.5
The major site of expression of PPARγ is in adipocytes, where two isoforms, PPARγ1 and
PPARγ2, are transcribed. While PPARγ2 is adipocyte specific and is the major form
expressed in adipocytes, PPARγ1 is expressed at lower levels in multiple cell types and has
been detected in macrophage derived foam cells in atherosclerotic plaques.6 PPARγ has
emerged as an important regulator of scavenger receptor CD-36, which can affect lipid
accumulation in the macrophages.7 On the other hand, PPARγ has also been implicated in
lipid efflux from macrophages through the activation of ABCA1 (ATP-Binding Cassette
A1).8 Consistent with its role in efflux, high fat fed LDLR-deficient mice reconstituted with
bone marrow from mice with macrophage-specific deletion of PPARγ had increased
atherosclerosis compared to mice reconstituted with wild type bone marrow.8,9 In the
vasculature, PPARγ1 isoform is expressed in endothelial cells and vascular smooth muscle
cells, and plays a role in blood pressure regulation.10 Also in high-fat fed LDLR-deficient
mice, endothelial cell-specific deletion of PPARγ accelerated atherosclerosis11, and smooth-
muscle cell specific PPARγ disruption enhanced angiotensin II induced atherosclerosis in
males.12
While global lack of PPARγ is incompatible with development and not observed in humans,
there are polymorphisms that subtly affect its function. Among them are various point
mutations that affect adipose tissue distribution and insulin sensitivity. For example,
mutations in the ligand binding domain at the C-terminus of the protein increase its binding
to co-repressors but impair binding to co-activators.13 Since these mutant proteins retain
DNA binding ability, they cause dominant-negative reduction of PPARγ activity in
heterozygotes. One of these mutations, Pro to Leu substitution at position 467, was
originally identified in patients with severe insulin resistance, hyperglycemia, lipodystrophy
and hypertension.14 Mice heterozygous for the corresponding P465L mutation also have ~8
mmHg higher blood pressure than normal and have mild hyperinsulinemia with an increased
pancreatic islet mass particularly on high-fat diet.15 However, they exhibit normal plasma
glucose and insulin sensitivity, unless they are stressed by severe obesity16 or by
suppression of insulin production.17 In the present study, we evaluated the effects of the
P465L mutation on the development of atherosclerosis in mice lacking apolipoprotein E
(apoE). Detrimental effects of the mutation on body fat distribution and blood pressure are
present in mice with apoE deficiency. Conversely, small, potentially athero-protective
changes were also detectable in macrophage lipid metabolism and vascular VCAM1
expression. Overall, however, the P465L mutation in PPARγ exhibited no detectable effects
on the atherosclerotic plaque development in the apoE-null mice.
Methods
Generation of Mutant Mice and Diet
PpargP465L/+ heterozygous mice15 were crossed with Apoe−/− mice18, both on the inbred
129S6/SvEvTac background. PpargP465L/+Apoe−/− mice were crossed with Apoe−/− mice to
generate littermates with P465L mutation (L/+) or without (+/+) for experiments. Genotypes
of mice were determined as previously described.15 The mice were fed normal rodent chow
(NC, Lab Diet 5P76; PMI Nutrition International), or a high fat western type diet containing
21% (w/w) fat and 0.15% (w/w) cholesterol (HFW, TD88137; Harlan Teklad). Animals
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were handled following procedures approved by the Institutional Animal Care and Use
Committee at The University of North Carolina at Chapel Hill.
Blood pressure (BP) measurements
BP and pulse rate were measured by tail-cuff method and were calculated from the mean of
30 daily measurements for 6 consecutive days.19
Glucose and lipid metabolism
Animals were fasted for 4 hours prior to the blood collection. Plasma glucose and
cholesterol were measured by colorimetric assay (Wako Chemicals USA Inc). Plasma
triglycerides were measured with reagents from Stanbio Lab. Glucose tolerance, liver TG
secretion and fat tolerance were determined on 4–5 months old male mice of each genotype
after 4h fast.15,20 Plasma insulin, resistin and leptin were measured by multiplex
immunoassays (Luminex), and adiponectin was measured by ELISA.21 Males on HFW were
treated with heparin (100U/kg body weight) and plasma lipase activity was measured with
4-methylumbelliferyl heptanoate (RPI Corp) as described.23
Peritoneal macrophage lipoprotein uptake and cholesterol efflux
Mice were given intraperitoneal injections of sterile 4% thioglycollate (BD Biosciences) in
PBS. Four days later, macrophages were collected by peritoneal lavage into PBS.
Macrophages were cultured in F-10 medium supplemented with 10% fetal bovine serum,
100 units/ml penicillin, 100 µg/ml streptomycin, and 2 mM L-glutamine. Very low density
lipoproteins (VLDL) were isolated from Apoe−/− mice, labeled with 1,1’-dioctadecyl-3,3,3’,
3’-tetramethylindocarbocyanine perchlorate (DiI C18; Molecular Probes) and macrophage
uptake of VLDL was measured as described.25 For cholesterol efflux, peritoneal
macrophages were cultured in a serum-free F-10 medium for 24 hours prior to incubation
with 2µCi/ml H3-cholesterol (Perkin-Elmer) with or without acetylated human LDL for 24
hours. Cells were washed and incubated in F-10 medium with or without 10 µg/ml of
apolipoprotein A1 (apoA1, Sigma) for 24 hours. Efflux was calculated as a ratio of
radioactivity in the medium divided by the total in cells and medium.23
Bone Marrow Transfer
Bone marrow cells were collected from femurs and tibias of donor male mice by flushing
with F-10 medium. Apoe−/− female recipients were lethally irradiated (9.5 grays) at 10
weeks of age, and injected with 2 × 106 bone marrow cells in 0.2 ml of medium through tail
veins.23
Atherosclerotic Lesion
Mice were sacrificed using an overdose of 2,2,2-bromophenol and perfused with heparinized
PBS and 4% paraformaldehyde. The aortic root was serially sectioned and stained with
Sudan IVB and Hematoxylin. Atherosclerosis was scored as described.24,18
Gene expression
Total RNA was purified from tissues using Automated Nucleic Acid Workstation ABI 6700,
and real-time PCR was performed in ABI PRISM 7700 Sequence Detector (Applied
Biosystems). β-Actin mRNA was used for normalization. Primers and probe sets used are
available online at http://atvb.ahajournals.org.
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Values are reported as mean±SEM. Two-way ANOVA with genotype and sex as two factors
was used for analyses. Student’s t test was used for comparisons between genotypes.
Results
General Phenotypes and Glucose Metabolism
PpargP465L/+Apoe−/− mice and Pparg+/+Apoe−/− mice were born in the expected Mendelian
ratio, appeared healthy and gained weight normally. General phenotypes of mice fed normal
chow (NC) and high fat diet (HFW) are summarized in Supplemental Tables S1 and S2,
respectively. Blood pressure of the PpargP465L/+Apoe−/− mice was significantly elevated
compared to Pparg+/+Apoe−/− littermates by about 8 mmHg regardless of diet (Figure 1A,
P456L effect P<0.03 in NC and HFW). Thus, the hypertensive effects of the PPARγ-P465L
mutation are retained on the apoE-deficient background.
Previously we identified that PPARγ-P465L causes altered body fat distribution in mice,17
and this effect was also present in mice on apoE-null background. Although animals had
similar body weights and total body fat content, PpargP465L/+Apoe−/− mice had a smaller
visceral (perigonadal) adipose tissue mass but larger subcutaneous (inguinal) adipose tissue
mass when compared to the corresponding fat depots in Pparg+/+Apoe−/− mice (Figure 1B).
Consequently, PpargP465L/+Apoe−/− mice had a significantly higher inguinal to perigonadal
ratio than the Pparg+/+Apoe−/− littermate controls (Table S1, S2). Individual inguinal fat
cells were larger (Figure 1C, median area 1222µm2 vs 760µm2), suggesting that the cell
number is not increased. Increased inguinal fat cell size is associated with increased
expressions of lipoprotein lipase (LPL) and resistin, and with decreased uncoupling protein
1 (UCP1). Expressions of adipocyte fatty acid binding protein (aP2) and adiponectin were
not different (Figure 1D). HFW increased the total amount of adipose tissue in both
genotypes. However, fat distribution (IF/GF) ratio remained similar to that on NC diet
(Tables S1 and S2).
Fasting plasma glucose levels were higher in male than female mice and higher in mice fed
a HFW (Figure 2A). The levels were slightly lower in PpargP465L/+Apoe−/− mice than in
Pparg+/+Apoe−/− mice, but the overall genotype effect was not significant.
PpargP465L/+Apoe−/− and Pparg+/+Apoe−/− mice also handled a bolus of glucose equally
well (Figure 2B). The fasted plasma insulin levels were not significantly different between
the two genotypes (Figure 2C). PPARγ regulates the expression of adipokines. While
plasma leptin levels were the same, resistin levels in the PpargP465L/+Apoe−/− mice were
two-fold higher while adiponectin levels were two-fold lower than in the Pparg+/+Apoe−/−
mice (Figure 2D–F).
Together, these data demonstrate that the effects of PPARγ-P465L on body fat distribution,
blood pressure regulation, and glucose metabolism persist in apoE-deficient mice. These
phenotypes are well-known risk factors for atherosclerosis.
Lipid Metabolism
ApoE deficiency causes plasma accumulation of cholesterol-rich remnants of chylomicrons
and very low-density lipoproteins (VLDL). Plasma cholesterol was not different between the
PpargP465L/+Apoe−/− and Pparg+/+Apoe−/− mice on normal chow diet (Table S1).
Cholesterol levels increased four-fold in both genotypes with HFW; however, there was no
genotype difference (Table S2). The overall distribution of plasma cholesterol among
lipoproteins as assessed by fast protein liquid chromatography was also not different (Figure
3A, 3B).
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Fasted plasma TG levels tended to be slightly lower in the PpargP465L/+Apoe−/− mice than in
Pparg+/+Apoe−/− mice on NC, although the difference was not statistically significant. While
plasma TG levels increased in both genotypes in response to HFW, the PpargP465L/+Apoe−/−
mice had a significantly smaller increase than the Pparg+/+Apoe−/− controls, particularly in
males (Figure 3C). Plasma TG values are a function of lipid absorption, rate of clearance
and liver TG synthesis and secretion. Despite the difference in plasma TG, the post-prandial
lipid handling as assessed by a lipid tolerance test (Figure 3D) and the secretion of TG from
the livers measured under the inhibition of lipolysis by Tyloxapol injection (Figure 3E, 3F)
were not different between the PpargP465L/+Apoe−/− and Pparg+/+Apoe−/− mice regardless of
diet. The difference in plasma TG may be explained by the higher LPL activity as
PpargP465L/+Apoe−/− inguinal fat tissues express 2.3 times higher LPL (Figure 1F), but the
total lipase activities in heparinized plasma were not different (data not shown).
Taken together, these data demonstrate that the hypercholesterolemia of apoE-null mice is
not affected by the PPARγ-P465L mutation. However, a trend of reduced plasma TG levels
in the PpargP465L/+Apoe−/− mice could protect them from atherosclerosis.
Atherosclerosis
We next measured the average size of atherosclerotic plaques in the aortic roots of 5-month
old NC fed mice and 4-month old mice fed HFW diet for 2 months. Contrary to our
expectation, the lesion size in Pparg+/+Apoe−/− and PpargP465L/+Apoe−/− mice did not differ
in either dietary condition (Figure 4A, 4B). Since our mice are 129S6 inbred background,
they developed significant amount of plaques in the aortic arch,18 but without detectable
differences in the plaque covered areas between PpargP465L/+Apoe−/− and Pparg+/+Apoe−/−
(Tables S1, S2). The plaques in PpargP465L/+Apoe−/− mice and Pparg+/+Apoe−/− mice
equally increased in size and complexity with age (Figure 4C–F), and plaque compositions
based on histological assessment of the occurrence of fibrous cap, necrotic core cholesterol
clefts and calcifications were similar (Supplemental Table S3). Immunohistochemical
staining of similar sized plaques for macrophages, T-cells and smooth muscle cells was not
remarkably different (Supplemental Figure S1). Taken together, we conclude that the
dominant negative PPARγ-P465L mutation has no effect on overall atherosclerotic plaque
development in apoE-null mice.
Macrophage Function
Peritoneal macrophages from PpargP465L/+Apoe−/− mice had a small but significant
reduction (11%) in DiI labeled VLDL uptake, compared to the Pparg+/+Apoe−/− controls
(Figure 5A). Furthermore, when macrophages were incubated with 3H-labeled cholesterol
for 24 hours (unloaded), cholesterol incorporation into the cells was significantly lower at
about 75% (Figure 5B), and apolipoprotein A1 stimulated cholesterol efflux by
PpargP465L/+Apoe−/− macrophages during the following 24 hours was significantly higher
than Pparg+/+Apoe−/− macrophages (Figure 5C). However, when the macrophages were
loaded with cholesterol in the presence of acetylated human LDL to model foam cells
(AcLDL-loaded), cholesterol incorporation and efflux were not different and apolipoprotein
A1 equally stimulated cholesterol efflux from PpargP465L/+Apoe−/− and Pparg+/+Apoe−/−
macrophages.
To test the functions of PpargP465L/+Apoe−/− macrophages in the atherosclerotic lesion
development in vivo, we next harvested bone marrows from PpargP465L/+Apoe−/− and
Pparg+/+Apoe−/− male mice and transplanted them into 10 week-old Pparg+/+Apoe−/−
female recipients. Two months after the transfer, the size of the foam cell lesions in the
aortic sinus of the mice that received PpargP465L/+Apoe−/− bone marrow were not
significantly different from those that received the Pparg+/+Apoe−/− marrow (Figure 5D).
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Plaques were mostly of early stages of foam cell lesions in the recipients of bone marrows
from either genotype (not shown). Taken together, the presence of PPARγ-P465L mutation
reduced macrophage lipid accumulation and enhanced cholesterol efflux from unloaded
macrophage. However, PPARγ-P465L appears to have no effects on cholesterol efflux once
foam cells are formed, and has little effects on atherosclerosis development in the
hyperlipidemic apoE-null animals.
Macrophage and vascular gene expressions
Since macrophages lacking PPARγ are reported to have impaired cholesterol efflux with
reduced ABCA-1 expression, we sought the effects of dominant-negative P465L mutation
on the expression of genes important for cholesterol metabolism in macrophage (Figure 6A).
We found a small increase in ABCA-1 and a small decrease in CD36 in
PpargP465L/+Apoe−/− macrophages compared to Pparg+/+Apoe−/− littermates, but the
differences were not significant. Although DiI-VLDL uptake was reduced, genes that may
influence VLDL uptake and cellular cholesterol contents in macrophage including SRB1
and LDLR were not different. VLDLR expression tended to be higher in
PpargP465L/+Apoe−/− macrophage, although again the difference was not statistically
significant.
Inflammatory response genes such as TGFb1, IL6 and iNOS differed widely in individual
macrophage isolates but were not significantly different between the two genotypes.
Notably, at an individual animal basis, the level of CD36 expression is strongly and
positively correlated with PPARγ mRNA levels (r=0.72), while it is negatively correlated
with ABCA1 mRNA levels (r=− 0.4, Figure 6B). ABCA1 mRNA levels are in turn
positively correlated with the iNOS gene expression (r=0.68), suggesting that the
inflammatory state of the macrophage as well as PPARγ influence the expression of genes
for lipid metabolism in macrophage.
To assess macrophage infiltration and vessel response, we next measured mRNA levels of
genes in the aortic arches of PpargP465L/+Apoe−/− and Pparg+/+Apoe−/− mice at 3 months of
age when foam cells just begin to accumulate in aortic arch (Figure 6C). No difference was
found in the expression of a macrophage marker CD68, ATP-binding cassette transporter G1
(ABCG1) that mediates free cholesterol efflux, or LPL, consistent with the histological
observations. Expression of osteopontin (SPP1), ABCA1 and endothelial nitric oxide
synthase (eNOS) in PpargP465L/+Apoe−/− aortas trended higher than in Pparg+/+Apoe−/−
aortas. In contrast, the basal expression of vascular cell adhesion molecule 1 (VCAM1) was
significantly reduced to 40% in the PpargP465L/+Apoe−/− compared to in the
Pparg+/+Apoe−/− vessels. These findings suggest that the PPARγ-P465L could be athero-
protective in aorta, but that macrophages accumulate in the vessels with a similar rate in
PpargP465L/+Apoe−/− and Pparg+/+Apoe−/− aortas in the very early stage of plaque
development.
Discussion
PPARγ has been implicated in the pathogenesis of atherosclerosis through its regulation of
circulating lipid and glucose levels and also by modulating vascular cell functions. All the
characteristics of the PPARγ-P465L mutation previously observed in mice with wild type
apoE were present in PpargP465L/+Apoe−/− mice, including increased blood pressure,
moderate hyperinsulinemia and altered body fat distribution. Hypercholesterolemia of the
apoE-null mice was not affected by the PPARγ-P465L mutation. Overall, however, we
observed no detectable differences in the size or complexities of the aortic root plaques in
PpargP465L/+Apoe−/− mice fed NC or 2 months of HFW, or in Apoe−/− mice replaced with
PpargP465L/+Apoe−/− bone marrow. Our data unequivocally demonstrate that the dominant-
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negative PPARγP465L mutation alone has no effect on plaque development in apoE-
deficient mice.
Hypertension is a well-known risk factor for atherosclerosis. ApoE-null mice with elevated
BP caused by genetic lack of eNOS25, lack of natriuretic peptide receptor A26, or infusion of
angiotensin II in circulation27, all develop enhanced atherosclerosis, which is attenuated by a
reduction in BP. We therefore hypothesized that the elevated BP associated with the
PPARγ-P465L would accelerate atherosclerosis in PpargP465L/+Apoe−/− mice. Although an
8 mmHg increase is modest, hypertension in the PpargP465L/+Apoe−/− mice is a potential
pro-atherogenic factor. Yet, there was no enhanced atherosclerosis in the
PpargP465L/+Apoe−/− mice compared to the Pparg+/+Apoe−/− mice. This suggests that either
this degree of BP increase alone is not sufficient to promote atherogenesis, or the
mechanism by which PPARγ-P465L cause elevated BP is not directly relevant to plaque
development. Cerebral arterioles expressing PPARγ-P465L mutation show increased
contraction to serotonin and endothelin 1, and impaired relaxation to acetylcholine.28
However, response to acetylcholine is not impaired in aorta, implying that PPARγ affects
resistance vessels more than larger conduit vessels.28 Further studies on the role of PPARγ
in the interaction between BP regulation and atherosclerosis are warranted.
Our PpargP465L/+Apoe−/− mice have increased plasma resistin and decreased plasma
adiponectin; the profile associated with obesity, insulin resistance and increased
inflammatory diseases in subjects with metabolic syndrome.29 Resistin antagonizes insulin
function. Its expression is high in adipose tissues in rodents and we found that its expression
in inguinal fat in PpargP465L/+Apoe−/− mice is elevated. Primary site of resistin expression in
humans is mononuclear cells in blood and, although role of resistin in glucose homeostasis
in humans is controversial and causative roles are yet to be established, resistin is strongly
associated with inflammatory diseases, including atherosclerosis.30 Adiponectin, in contrast,
has insulin sensitizing and anti-inflammatory properties and its expression is regulated by
PPARγ. Reduction of plasma adiponectin must be mainly the consequence of reduced
production from the perigonadal fat, since adiponectin gene expression in inguinal fat of the
PpargP465L/+Apoe−/− mice was not altered. While inguinal fat mass in these mice was
increased, individual adipocyte cell size is also increased resulting in unaltered total
adipocyte number. Together, plasma adipokine profile of the PpargP465L/+Apoe−/− mice is
consistent with reduced PPARγ activity and is suggestive of a pro-inflammatory state.
However, the role of adiponectin in rodent atherosclerosis is controversial, since adenovirus
mediated adiponectin overproduction in the liver of apoE−/− mice reduced atherosclerosis31
but neither deficiency nor overproduction altered atherosclerosis in LDLR−/− mice.32
Some anti-atherosclerotic factors may be counteracting the pro-atherogenic effects of high
BP, lipodystrophy and adipokine profile in the PpargP465L/+Apoe−/− mice. For example, we
established previously that mice with PPARγ-P465L exhibit normal glucose handling in
part because of increased release of postplandial insulin.15, 17 When global insulin signaling
is intact, increased insulin could be anti-atherogenic, since insulin has vasodilatory and anti-
inflammatory properties.33 Consistent with this, loss of insulin signaling in vascular cells
accelerated atherosclerosis34, while chronic oral administration of insulin attenuated
atherosclerosis.35 Reduced plasma TG in the PpargP465L/+Apoe−/− mice is also potentially
anti-atherogenic.
PPARγ appears to play a complex and multi-faceted role in macrophages, affecting the
recruitment and activation of monocytes, cholesterol homeostasis and inflammation. PPARγ
activation has been shown to increase the expression of scavenger receptor CD36, which is
associated with lipid accumulation in the macrophage.6,7 For example, while the basal gene
expression levels of CD36 were similar between wild type and PPARγ-deficient
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macrophages, treatment of wild type mice with rosiglitazone resulted in a robust up-
regulation of CD36 expression in a PPARγ-dependent manner.7 In our PpargP465L/+Apoe−/−
mice, the gene expression of CD36 in thioglycolate-induced macrophages was ~25% lower
than in Pparg+/+Apoe−/− macrophages, with the difference approaching statistical
significance. This reduction in basal gene expression likely contributes to the reduced lipid
accumulation in the unloaded PpargP465L/+Apoe−/− macrophages. In addition, we observed a
significant reduction in DiI labeled VLDL uptake compared to macrophages isolated from
the Pparg+/+Apoe−/− mice.
PPARγ activation also induces macrophage expression of ABCA-1, and the conditional
disruption of PPARγ in murine macrophages reduces cholesterol efflux via reduction in
ABCA-1 transcription.8 This mechanism may account for the 50% increase in
atherosclerosis in both high-fat fed wild type C57BL/6 and LDL receptor deficient mice
reconstituted with bone marrow from mice with a macrophage-specific knockout of
PPARγ.8,9 In our study, the expression of ABCA-1 in macrophage was slightly higher, if
any, and unloaded PparP465L/+Apoe−/− macrophage had a two-fold higher rates of
cholesterol efflux. However, once the PPARγ-P465L cells were loaded with acetylated
cholesterol and became foam cell like, the enhanced ability of PPARγ-P465L macrophages
to efficiently efflux cholesterol compared to Pparg+/+Apoe−/− controls disappeared.
Although the reduced uptake and increased cholesterol efflux may point to an athero-
protective phenotype, the loss of advantage in efflux under excess cholesterol load may
explain the lack of a reduction in the lesions in our bone marrow transfer experiments.
While the expression of CD36 in peritoneal macrophages was highly correlated with the
levels of PPARγ gene expression at individual isolate levels, we found that ABCA1
expression was not directly correlated with the PPARγ gene expression. It was, instead,
positively correlated with iNOS gene expression, suggesting the role of the inflammatory
states in the regulation of ABC-A1 gene in macrophages. This effect was, however,
independent of PPARγ-P467L mutation.
Consistent with histological observations, our analysis of gene expression in the aortic arch
demonstrated that the recruitment and activation of macrophage in the vessel wall is not
significantly different between PpargP465L/+Apoe−/− and Pparg+/+Apoe−/− mice at an early
stage of atherosclerosis. An exception is that the expression of VCAM-1 was significantly
lower in the PpargP465L/+Apoe−/− vessels than in Pparg+/+Apoe−/− vessels. VCAM-1 binds
to α4β1 integrin, which is expressed on leukocytes, and mediates rolling and adhesion to
endothelium.36 The reduced expression of VCAM-1 could be anti-atherogenic, since
hypomorphic mutant form of VCAM-l has been shown to protect LDLR-null mice from
atherosclerosis.36 In human atherosclerotic plaques, VCAM-1 is not expressed in normal
vessels but is focally expressed in endothelial cells and strongly in “spindle shaped cells of
macrophage type” in lipid-containing plaques.37 However, since overall expression of
macrophage markers including CD68 and SPP1 genes are not different between the two
groups, the significance of a reduced VCAM1 expression in the PpargP465L/+Apoe−/− mice
is not clear, and requires further study.
It is important to acknowledge that PPARγ is identified as a crucial athero-protective
molecule primarily with a use of pharmacological drugs, which may exert PPARγ
independent effects, or in the LDLR null mice that lack PPARγ in specific tissues while
present in the rest of the body. Our genetic model is maintained on inbred 129/SvEv
background, which ensures that no polymorphic variations present in different inbred mouse
strains are accidentally segregating with the PPARγ-P465L mutation and obscuring its
effects. In this model, a reduction of PPARγ function due to the P465L mutation affects the
whole body, and therefore cross talks between different cell and organ systems are intact.
Consequently, the balance between mild pro-atherogenic and anti-atherogenic effects of the
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PPARγ-P465L mutation can mutually dampen the potential deleterious effects in a single
cell type or organ, as observed in the experiments of tissue specific knockouts. The lack of
demonstrable PPARγ-P465L effects on atherosclerosis of the apoE null mice can also be
attributable to altered function of the mutant PPARγ, as dominant -negative mutations are
different from full deletion. Thus severe hypercholesterolemia in apoE-deficient mice may
not only mask small deleterious effects of PPARγ-P465L, but may even increase the
availability of some endogenous PPARγ ligands which allow overcome dominant-negative
effects of P465L substitution.38 Finally, we note that one of the athero-protective roles of
PPARγ is an induction of apoE expression in macrophages which helps cholesterol
efflux39,40, and this induction is missing in apoE-null model. The possibility that the
PPARγ-P456L mutation may differentially alter the phenotype of some other model of
atherosclerosis retaining endogenous apoE expression, such as LDLR-null mice, cannot be
eliminated.
In conclusion, we found that the dominant negative PPARγ-P465L mutation has no overall
effect on atherosclerotic plaque formation in apoE-null model. While this specific mutation
is rare in humans, its effects mimic those of other mutations and polymorphisms present in
the human population.
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Elevated blood pressure and altered body fat deposition in apoE-deficient mice with PPARγ
P465Lmutation (Lee, black bars) compared to those with wild type PPARγ (Wee, white
bars). (A, B), blood pressure in mice on normal chow (NC) and on a western type high fat
diet (HFW). Inguinal fat (C) and perigonadal fat weights (D) in NC fed mice are expressed
as % of body weights. (E), Distribution of cell size in inguinal adipose tissues. Over 2500
cell were measured from 5 mice in each genotype and expressed as % in each size range.
Open circles, Wee; filled circles, Lee. (E), mRNA for PPARg target genes in inguinal
adipose tissues. LPL gene expression in inguinal fat of Lee female mice on NC relative to
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the mean of mRNA levels in Wee females. Numbers in the bars are the number of mice
used. * P<0.01 between the two genotype groups.
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Glucose metabolism in the PpargP465L/+Apoe−/− (Lee) and Pparg+/+Apoe−/− (Wee) mice.
(A), Fasting plasma glucose levels. (B), Oral glucose tolerance tests on male mice (n=6) on
normal chow (NC) or a high fat western diet (HFW). Plasma levels of insulin (C), leptin (D),
resistin (E) and adiponectin (F) in male mice. Black bars and black circles indicate Lee mice
and white bars and white circles indicate Wee mice. Numbers in the bars are the number of
mice used. * P<0.05 between genotypes, # P<0.05 between the diets.
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Lipid metabolism in the PpargP465L/+Apoe−/− (Lee) and Pparg+/+Apoe−/− (Wee) mice.
Distribution of cholesterol (A) and triglycerides (B) among lipoproteins assessed by the fast
protein liquid chromatography of pooled plasma from females on NC (n=3 each). (C),
Plasma triglyceride levels. (D), Plasma triglycerides after lipid loading with gavage. (E, F)
Liver triglyceride secretion after tyloxapol injection in 4 months old males fed NC or HFW.
White dots and white bars represent Wee mice, black dots and black bars represent Lee
mice.
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Atherosclerosis. Average plaque size in the aortic roots of Pparg+/+Apoe−/− (Wee, white
bars) and PpargP465L/+Apoe−/− (Lee, black bars) mice fed normal chow at 5 months of age
(A), or fed high fat diet at 4 months of age (B). The numbers within the bars indicate sample
size. (C), Cross sections at the aortic roots of 7 months old Wee and Lee male littermate
mice on normal chow. Bottom panels are plaques near the coronary ostiums from another set
of littermates.
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Function of macrophage from Pparg+/+Apoe−/− (Wee, white bars) and PpargP465L/+Apoe−/−
(Lee, black bars). (A), Uptake of DiI labeled VLDL from the medium by macrophages. (B),
Relative cellular H3 cholesterol uptake after incubation without (unloaded) and with
acetylated human LDL (AcLDL loaded). (C), Cholesterol efflux in the absence or presence
of apolipoprotein A1 from peritoneal macrophages labeled with H3 cholesterol without
(unloaded) and with acetylated human LDL (Loaded). At least 6 wells were used for
macrophages isolated from each mouse (three mice of each genotype). * P<0.05 between the
two genotypes. #P<0.05 for apoA1 effects. (D) Plaque size in the aortic roots of apoE-
Pendse et al. Page 18













deficient females receiving bone marrows from Wee (white bars) or Lee (black bars) male
donors.
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Gene expression normalized to β-actin in peritoneal macrophages isolated from
Pparg+/+Apoe−/− (Wee, white bars) and PpargP465L/+Apoe−/− (Lee, black bars). Data are
mean±SE expressed relative to the mean of Wee. (B), Scatterplot matrix of gene expressions
for PPARγ, ABCA1, CD36 and iNOS (in log scale) in individual macrophage isolates.
Density ellipses are set at α=0.95. Open circles are Wee and closed circles are Lee. (C),
Gene expression in the aortic arch of 3 month old mice on normal chow. Data are expressed
relative to the mean mRNA amount of each gene in Wee mice as 100. N>17 except for n=6
each. *, P<0.01.
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